Real Health

The AIDS virus was discovered there almost 25 years. In 1996, with the advent of triple therapy, the treatment has made a leap forward: the life expectancy of people infected with HIV has increased and mortality has dropped by 40%. Patient comfort and organization of treatment are now a new important step with the market Atripla ®, available first triple in a single tablet.

AIDS is one of the major scourges of our time. There are now about 33 million people living with this infection in the world. Even if one does not always cure the disease, thanks to triple infection appears more like a death sentence, at least in countries with accessS treatment … Result, AIDS is more of a chronic disease more than a fatal disease in itself.

Patients should, however, is given a heavy and sometimes difficult life. In 2004, the secretary of state in the U.S. health care, Tommy Thompson, had called the main pharmaceutical players in the fight against AIDS to work together on a simplified treatment. This callborne fruit: the association of laboratories Bristol-Myers Squibb and Gilead has helped in 1 year and a half to develop Atripla ®.

After 5 tests formulation, the two companies have launched in the United States in 2007 this triple into a tablet. The Atripla ® combines 3 antiretrovirals in 1 single tablet to be taken in the evening at bedtime. these 3 active ingredients are known efavire -nz, emtricitabine and tenofovir inhibit and 3 different ways of reverse transcriptase, an enzyme that enables HIV to establish itself within infected cells.

Atripla ® is indicated in adults for the treatment of infection by HIV-1 to replace a first treatment that allowedto have an undetectable viral load for over 3 months. The Atripla ® is to be taken in the evening, at bedtime: "An integrated low binding in the lives of patients argue laboratories.

The objective of this tablet is to make monitoring more simple and to promote its adherence or adherence absolute key to survival.

However this is not the médicame nt ideal, since the known adverse effects of such substances may require discontinuation, even though studies by the laboratories have a good safety profile. The fact that the doses are fixed also limit its use. Nevertheless it is a significant advance in terms of comfort and reduction of constraints, which should increase compliance and thus the survival of patients.

: justify "> The Atripla ® has received approval to market in the 27 EU countries in December 2007 and is available in France since early in pharmacies and hospitals of the city. A new step towards better management of this serious disease.

Sources: Press Kit "Atripla ®, the era of simplicity in the treatment of HIV", May 2009